Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > TBP SIGNS LICENSE AGRMNT WITH THORNE HEALTH/PREBIOTIC SUPLMN

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Feb 22, 2022 8:52am

132 Views

Post# 34449536

RE:TBP SIGNS LICENSE AGRMNT WITH THORNE HEALTH/PREBIOTIC SUPLMN

This is new. Nr do not offer details. How? Sales team in the us? thrn looks relatively big at 250M mc. So to give it sale Tbp in the us is something but do Tbp have any sales team there? It is a revenue creation activity beside our cannabis I think details are required. Maybe a follow interview or nr will explain details. It is a positive development but more details are neede.

Humanist wrote: Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement

by @newswire on 22 Feb 2022, 06:30

OTTAWA, ON, Feb. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, today announced it has signed a Licensing Agreement with Thorne Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, for the commercialization of its patent protected prebiotic dietary supplement in the U.S. market.

The Agreement will include royalty on sales and milestone payments. The prebiotics market size in the United States is expected to exceed USD 9.5bn by 2027 with a strong CAGR of 9.6% in 2021.
"Thorne has an established reputation as a world leader in the sales and distribution of evidence-based supplements for consumer self-care and physician-directed therapies and Tetra is excited to partner with them to bring this product to market," said Guy Chamberland, CEO of Tetra Bio-Pharma.
= Global Marketing Insights (GMI) Insights to Innovation April 14, 2021

About Thorne HealthTech
Thorne HealthTech is a leader in developing innovative solutions for a personalized approach to health and wellbeing. Thorne HealthTech is a science-driven wellness company that is utilizing testing and data to create improved product efficacy and deliver personalized solutions to consumers, health professionals, and corporations. Thorne HealthTech's unique, vertically integrated brands, Thorne and Onegevity, provide insights and personalized data, products, and services that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime.
About Tetra Bio-Pharma
Tetra Bio-Pharma is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra's evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians, and insurance companies.